Phase II Study of Weekly Paclitaxel in Patients with Non-Small Cell Lung Cancer Who Have Failed Previous Treatments

Publisher： Karger

E-ISSN： 1423-0232|66|5|347-352

ISSN： 0030-2414

Source： Oncology, Vol.66, Iss.5, 2004-09, pp. : 347-352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

By  

Oncology, Vol. 79, Iss. 5-6, 2011-04 ,pp. : 423-429

Karger

Access to resources Recommend Favorite

Phase II Trial of Weekly Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 224-228

Karger

Access to resources Recommend Favorite

Phase II Study of Irinotecan and Ifosfamide in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 306-311

Karger

Access to resources Recommend Favorite

Paclitaxel, Carboplatin, and G-CSF in Advanced Non-Small-Cell Lung Cancer: A Phase I/II Study

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 310-314

Karger

Access to resources Recommend Favorite

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2253-2261

John Wiley & Sons Inc

Access to resources Recommend Favorite